Document Detail


Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction: multicenter study.
MedLine Citation:
PMID:  3320390     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of intracoronary urokinase (UK) in an acute myocardial infarction has not been firmly established in a randomized fashion. Two hundred and ten patients were randomized to UK therapy (107 patients) and placebo (103 patients). Successful recanalization was achieved in 74% of the UK group vs 17% in the placebo group (p less than 0.01). The success rate was dose dependent up to 960,000 I.U. Clinical course was favorable and left ventricular enddiastolic pressure was reduced significantly in the UK group compared with the placebo group (p less than 0.05). Ejection fraction one month after the study was better in the reopened group than in the occluded group. Thus, early administration of UK can establish coronary reflow in a high proportion of patients and appears to favor the clinical course.
Authors:
H Kambara; K Kammatsuse; M Nobuyoshi; K Kodama; H Sato; S Sasayama; N Kajiwara; M Nakashima; C Kawai
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Japanese circulation journal     Volume:  51     ISSN:  0047-1828     ISO Abbreviation:  Jpn. Circ. J.     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1988-02-04     Completed Date:  1988-02-04     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7806868     Medline TA:  Jpn Circ J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  1072-6     Citation Subset:  IM    
Affiliation:
Kyoto University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Clinical Trials as Topic
Coronary Circulation / drug effects
Double-Blind Method
Drug Evaluation
Electrocardiography
Female
Hemodynamics / drug effects
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*
Random Allocation
Stroke Volume
Urokinase-Type Plasminogen Activator / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet survival and serotonin content after placement of arterial prostheses in dogs: effects of n...
Next Document:  Fundamental and clinical studies of low-dose total body irradiation in tumor control